BDBM160475 US10093663, Example 26b::US20240109861, Compound LNP023::US9682968, Example-26a

SMILES CCO[C@H]1CCN([C@@H](C1)c2ccc(cc2)C(=O)O)Cc3c4cc[nH]c4c(cc3OC)C

InChI Key InChIKey=RENRQMCACQEWFC-UHFFFAOYSA-N

Data  9 IC50  1 Kd

PDB links: 1 PDB ID matches this monomer.

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 10 hits for monomerid = 160475   

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160475(US9682968, Example-26a | US10093663, Example 26b |...)
Affinity DataIC50: 0.0100nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160475(US9682968, Example-26a | US10093663, Example 26b |...)
Affinity DataIC50: 10nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160475(US9682968, Example-26a | US10093663, Example 26b |...)
Affinity DataIC50: 1.10E+3nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160475(US9682968, Example-26a | US10093663, Example 26b |...)
Affinity DataKd:  7.90nMAssay Description:Binding affinity to human serine protease factor B by SPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2021
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160475(US9682968, Example-26a | US10093663, Example 26b |...)
Affinity DataIC50: 12nMAssay Description:Inhibition of human serine protease factor B by TR-FRET based competition binding assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2021
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160475(US9682968, Example-26a | US10093663, Example 26b |...)
Affinity DataIC50: 130nMAssay Description:Inhibition of serine protease factor B in 50% human whole blood assessed as reduction in alternative pathway-mediated membrane attack complex formati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2021
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetComplement factor B(Mouse)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM160475(US9682968, Example-26a | US10093663, Example 26b |...)
Affinity DataIC50: 110nMAssay Description:Inhibition of serine protease factor B in 50% mouse serum assessed as reduction in C3b deposition pre-incubated for 15 mins before activated zymosan ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2021
Entry Details Article
PubMed
TargetComplement factor D(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM160475(US9682968, Example-26a | US10093663, Example 26b |...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human AP protein factor DMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2021
Entry Details Article
PubMed
TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160475(US9682968, Example-26a | US10093663, Example 26b |...)
Affinity DataIC50: 400nMAssay Description:Inhibition of human serine protease factor B in human PNH patient derived sample assessed as prevention of erythrocyte lysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2021
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetUromodulin(Human)
Medshine Discovery

US Patent
LigandPNGBDBM160475(US9682968, Example-26a | US10093663, Example 26b |...)
Affinity DataIC50: 38nMAssay Description:Serum was diluted with diluent (1:23). Drugs were added to the diluted serum with 8 concentration gradients of up to 10 mM or 50 mM in a 5-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent